Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PER2 | O15055 | 4/20 | 0.47 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | CLPP | Q16740 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2732426 | 0.95 | KDM4E (0.58) | KDM4ESMN1; SMN2BDKRB1CYP1A2CYP2C9 | |
| SCHEMBL1657335 | 0.85 | MAPK1 (0.66) | KDM4ESMN1; SMN2BDKRB1CYP1A2CYP2C9 | |
| SCHEMBL23638961 | 0.85 | CYP1A2 (0.50) | KDM4ESMN1; SMN2BDKRB1CYP1A2CYP2C9 | |
| SCHEMBL1424192 | 0.85 | BDKRB1 (0.50) | BDKRB1CYP1A2CYP2C9GRIA2KMT2A | |
| SCHEMBL2561525 | 0.85 | CYP1A2 (0.50) | KDM4ESMN1; SMN2BDKRB1CYP1A2CYP2C9 | |
| SCHEMBL28329769 | 0.81 | KMT2A (0.47) | BDKRB1CYP1A2CYP2C9GRIA2ADRA1B | |
| SCHEMBL5195011 | 0.81 | ALDH1A1 (0.58) | KDM4ESMN1; SMN2BDKRB1CYP1A2CYP2C9 | |
| SCHEMBL16759677 | 0.81 | ALDH1A1 (0.65) | KDM4ESMN1; SMN2CYP1A2CYP2C9KMT2A | |
| SCHEMBL1655584 | 0.80 | KMT2A (0.48) | BDKRB1CYP1A2CYP2C9GRIA2KMT2A | |
| SCHEMBL20818585 | 0.78 | KDM4E (0.48) | KDM4ESMN1; SMN2CYP1A2CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | KDM4E 364/4885SMN1; SMN2 3214/4885BDKRB1 4769/4885 |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | KDM4E 304/4885SMN1; SMN2 3078/4885BDKRB1 4724/4885 |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | KDM4E 364/4885SMN1; SMN2 3214/4885BDKRB1 4769/4885 |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | KDM4E 304/4885SMN1; SMN2 3078/4885BDKRB1 4724/4885 |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | KDM4E 304/4885SMN1; SMN2 3078/4885BDKRB1 4724/4885 |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | KDM4E 304/4885SMN1; SMN2 3078/4885BDKRB1 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.